Hepatocellular Carcinoma Treatment Market Segmentation
Frequently Asked Questions
2023 is the base year and 2030 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Hepatocellular Carcinoma Treatment Market Introduction
2.1.Global Hepatocellular Carcinoma Treatment Market - Taxonomy
2.2.Global Hepatocellular Carcinoma Treatment Market - Definitions
2.2.1.Route of Administration
2.2.2.Drug
2.2.3.Distribution Channel
2.2.4.Region
3.Global Hepatocellular Carcinoma Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Hepatocellular Carcinoma Treatment Market Analysis, 2018-2022 and Forecast 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5.Global Hepatocellular Carcinoma Treatment Market By Route of Administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Oral
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Injectable
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6.Global Hepatocellular Carcinoma Treatment Market By Drug, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Atezolizumab
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Avelumab
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Bevacizumab
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Durvalumab
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Erlotinib
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Gefitinib
6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Regorafenib
6.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Sorafenib
6.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
6.9. Tremelimumab
6.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.9.3. Market Opportunity Analysis
6.10. Cabozatinib
6.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.10.3. Market Opportunity Analysis
6.11. Ramucirumab
6.11.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.11.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.11.3. Market Opportunity Analysis
6.12. Others
6.12.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.12.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.12.3. Market Opportunity Analysis
7.Global Hepatocellular Carcinoma Treatment Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospital Pharmacy
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacy
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacy
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8.Global Hepatocellular Carcinoma Treatment Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
9.North America Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1.Oral
9.1.2.Injectable
9.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1.Atezolizumab
9.2.2.Avelumab
9.2.3.Bevacizumab
9.2.4.Durvalumab
9.2.5.Erlotinib
9.2.6.Gefitinib
9.2.7.Regorafenib
9.2.8.Sorafenib
9.2.9.Tremelimumab
9.2.10.Cabozatinib
9.2.11.Ramucirumab
9.2.12.Others
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1.Hospital Pharmacy
9.3.2.Retail Pharmacy
9.3.3.Online Pharmacy
9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1.Oral
10.1.2.Injectable
10.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1.Atezolizumab
10.2.2.Avelumab
10.2.3.Bevacizumab
10.2.4.Durvalumab
10.2.5.Erlotinib
10.2.6.Gefitinib
10.2.7.Regorafenib
10.2.8.Sorafenib
10.2.9.Tremelimumab
10.2.10.Cabozatinib
10.2.11.Ramucirumab
10.2.12.Others
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1.Hospital Pharmacy
10.3.2.Retail Pharmacy
10.3.3.Online Pharmacy
10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11.Asia Pacific (APAC) Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1.Oral
11.1.2.Injectable
11.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1.Atezolizumab
11.2.2.Avelumab
11.2.3.Bevacizumab
11.2.4.Durvalumab
11.2.5.Erlotinib
11.2.6.Gefitinib
11.2.7.Regorafenib
11.2.8.Sorafenib
11.2.9.Tremelimumab
11.2.10.Cabozatinib
11.2.11.Ramucirumab
11.2.12.Others
10.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1.Hospital Pharmacy
11.3.2.Retail Pharmacy
11.3.3.Online Pharmacy
11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Latin America Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1.Oral
12.1.2.Injectable
12.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1.Atezolizumab
12.2.2.Avelumab
12.2.3.Bevacizumab
12.2.4.Durvalumab
12.2.5.Erlotinib
12.2.6.Gefitinib
12.2.7.Regorafenib
12.2.8.Sorafenib
12.2.9.Tremelimumab
12.2.10.Cabozatinib
12.2.11.Ramucirumab
12.2.12.Others
11.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1.Hospital Pharmacy
12.3.2.Retail Pharmacy
12.3.3.Online Pharmacy
12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.4.1.Brazil
12.4.2.Mexico
12.4.3.Rest of LA
13.Middle East and Africa Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.1.1.Oral
13.1.2.Injectable
13.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.2.1.Atezolizumab
13.2.2.Avelumab
13.2.3.Bevacizumab
13.2.4.Durvalumab
13.2.5.Erlotinib
13.2.6.Gefitinib
13.2.7.Regorafenib
13.2.8.Sorafenib
13.2.9.Tremelimumab
13.2.10.Cabozatinib
13.2.11.Ramucirumab
13.2.12.Others
12.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.3.1.Hospital Pharmacy
13.3.2.Retail Pharmacy
13.3.3.Online Pharmacy
13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.4.1.GCC Countries
13.4.2.South Africa
13.4.3.Rest of MEA
14. Competition Landscape
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis)
14.2.1.AstraZeneca
14.2.2.Bayer AG
14.2.3.Bristol-Myers-Squibb Company
14.2.4.Celgene Corporation
14.2.5.Eisai Co. Ltd
14.2.6.Hoffmann-La Roche Ltd
14.2.7.Merck & Co. Inc.
14.2.8.Pfizer Inc.
14.2.9.Chugai Pharmaceutical Co. Ltd
14.2.10.Pharmaxis
14.2.11.Eli Lilly
14.2.12.BeiGene
15. Research Methodology
16. Appendix and Abbreviations
2.Global Hepatocellular Carcinoma Treatment Market Introduction
2.1.Global Hepatocellular Carcinoma Treatment Market - Taxonomy
2.2.Global Hepatocellular Carcinoma Treatment Market - Definitions
2.2.1.Route of Administration
2.2.2.Drug
2.2.3.Distribution Channel
2.2.4.Region
3.Global Hepatocellular Carcinoma Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Hepatocellular Carcinoma Treatment Market Analysis, 2018-2022 and Forecast 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5.Global Hepatocellular Carcinoma Treatment Market By Route of Administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Oral
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Injectable
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6.Global Hepatocellular Carcinoma Treatment Market By Drug, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Atezolizumab
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Avelumab
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Bevacizumab
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Durvalumab
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Erlotinib
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Gefitinib
6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Regorafenib
6.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Sorafenib
6.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
6.9. Tremelimumab
6.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.9.3. Market Opportunity Analysis
6.10. Cabozatinib
6.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.10.3. Market Opportunity Analysis
6.11. Ramucirumab
6.11.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.11.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.11.3. Market Opportunity Analysis
6.12. Others
6.12.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.12.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.12.3. Market Opportunity Analysis
7.Global Hepatocellular Carcinoma Treatment Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospital Pharmacy
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacy
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacy
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8.Global Hepatocellular Carcinoma Treatment Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
9.North America Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1.Oral
9.1.2.Injectable
9.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1.Atezolizumab
9.2.2.Avelumab
9.2.3.Bevacizumab
9.2.4.Durvalumab
9.2.5.Erlotinib
9.2.6.Gefitinib
9.2.7.Regorafenib
9.2.8.Sorafenib
9.2.9.Tremelimumab
9.2.10.Cabozatinib
9.2.11.Ramucirumab
9.2.12.Others
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1.Hospital Pharmacy
9.3.2.Retail Pharmacy
9.3.3.Online Pharmacy
9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1.Oral
10.1.2.Injectable
10.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1.Atezolizumab
10.2.2.Avelumab
10.2.3.Bevacizumab
10.2.4.Durvalumab
10.2.5.Erlotinib
10.2.6.Gefitinib
10.2.7.Regorafenib
10.2.8.Sorafenib
10.2.9.Tremelimumab
10.2.10.Cabozatinib
10.2.11.Ramucirumab
10.2.12.Others
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1.Hospital Pharmacy
10.3.2.Retail Pharmacy
10.3.3.Online Pharmacy
10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11.Asia Pacific (APAC) Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1.Oral
11.1.2.Injectable
11.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1.Atezolizumab
11.2.2.Avelumab
11.2.3.Bevacizumab
11.2.4.Durvalumab
11.2.5.Erlotinib
11.2.6.Gefitinib
11.2.7.Regorafenib
11.2.8.Sorafenib
11.2.9.Tremelimumab
11.2.10.Cabozatinib
11.2.11.Ramucirumab
11.2.12.Others
10.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1.Hospital Pharmacy
11.3.2.Retail Pharmacy
11.3.3.Online Pharmacy
11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Latin America Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1.Oral
12.1.2.Injectable
12.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1.Atezolizumab
12.2.2.Avelumab
12.2.3.Bevacizumab
12.2.4.Durvalumab
12.2.5.Erlotinib
12.2.6.Gefitinib
12.2.7.Regorafenib
12.2.8.Sorafenib
12.2.9.Tremelimumab
12.2.10.Cabozatinib
12.2.11.Ramucirumab
12.2.12.Others
11.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1.Hospital Pharmacy
12.3.2.Retail Pharmacy
12.3.3.Online Pharmacy
12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.4.1.Brazil
12.4.2.Mexico
12.4.3.Rest of LA
13.Middle East and Africa Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.1.1.Oral
13.1.2.Injectable
13.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.2.1.Atezolizumab
13.2.2.Avelumab
13.2.3.Bevacizumab
13.2.4.Durvalumab
13.2.5.Erlotinib
13.2.6.Gefitinib
13.2.7.Regorafenib
13.2.8.Sorafenib
13.2.9.Tremelimumab
13.2.10.Cabozatinib
13.2.11.Ramucirumab
13.2.12.Others
12.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.3.1.Hospital Pharmacy
13.3.2.Retail Pharmacy
13.3.3.Online Pharmacy
13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.4.1.GCC Countries
13.4.2.South Africa
13.4.3.Rest of MEA
14. Competition Landscape
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis)
14.2.1.AstraZeneca
14.2.2.Bayer AG
14.2.3.Bristol-Myers-Squibb Company
14.2.4.Celgene Corporation
14.2.5.Eisai Co. Ltd
14.2.6.Hoffmann-La Roche Ltd
14.2.7.Merck & Co. Inc.
14.2.8.Pfizer Inc.
14.2.9.Chugai Pharmaceutical Co. Ltd
14.2.10.Pharmaxis
14.2.11.Eli Lilly
14.2.12.BeiGene
15. Research Methodology
16. Appendix and Abbreviations
AstraZeneca
Bayer AG
Bristol-Myers-Squibb Company
Celgene Corporation
Eisai Co. Ltd
Hoffmann-La Roche Ltd
Merck & Co. Inc.
Pfizer Inc.
Chugai Pharmaceutical Co. Ltd
Pharmaxis
Eli Lilly
BeiGene
Bayer AG
Bristol-Myers-Squibb Company
Celgene Corporation
Eisai Co. Ltd
Hoffmann-La Roche Ltd
Merck & Co. Inc.
Pfizer Inc.
Chugai Pharmaceutical Co. Ltd
Pharmaxis
Eli Lilly
BeiGene